Header Logo

Connection

STEPHEN PFLUGFELDER to Ophthalmic Solutions

Back to Details
This is a "connection" page, showing publications STEPHEN PFLUGFELDER has written about Ophthalmic Solutions.
STEPHEN PFLUGFELDER
Connection Strength
3.156
Ophthalmic Solutions
  1. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010 Aug; 29(8):871-7.
    View in: PubMed
    Score: 0.350
  2. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009 May-Jun; 54(3):321-38.
    View in: PubMed
    Score: 0.321
  3. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea. 2008 Jun; 27(5):574-9.
    View in: PubMed
    Score: 0.301
  4. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008 Jan; 27(1):64-9.
    View in: PubMed
    Score: 0.293
  5. Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses. Ocul Surf. 2022 01; 23:162-168.
    View in: PubMed
    Score: 0.189
  6. [The effect of artificial tears on corneal surface regularity in dry eye]. Zhonghua Yan Ke Za Zhi. 2000 Mar; 36(2):131-4.
    View in: PubMed
    Score: 0.170
  7. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. Ophthalmology. 2020 01; 127(1):14-26.
    View in: PubMed
    Score: 0.164
  8. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology. 1999 May; 106(5):939-43.
    View in: PubMed
    Score: 0.161
  9. Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast. J Ocul Pharmacol Ther. 2018 09; 34(7):543-549.
    View in: PubMed
    Score: 0.151
  10. Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease. JAMA Ophthalmol. 2015 Oct; 133(10):1117-23.
    View in: PubMed
    Score: 0.125
  11. Effects of Dry Eye Therapies on Environmentally Induced Ocular Surface Disease. Am J Ophthalmol. 2015 Jul; 160(1):135-42.e1.
    View in: PubMed
    Score: 0.121
  12. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010 Jan; 128(1):94-101.
    View in: PubMed
    Score: 0.084
  13. A supplemental labeling system for topical medications. Am J Ophthalmol. 1987 Mar 15; 103(3 Pt 1):335.
    View in: PubMed
    Score: 0.069
  14. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006 Dec; 32(6):272-6.
    View in: PubMed
    Score: 0.068
  15. Integrating restasis into the management of dry eye. Int Ophthalmol Clin. 2006; 46(4):101-3.
    View in: PubMed
    Score: 0.064
  16. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005 Oct; 112(10):1790-4.
    View in: PubMed
    Score: 0.063
  17. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005 Jan; 24(1):80-5.
    View in: PubMed
    Score: 0.059
  18. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004 Sep; 138(3):444-57.
    View in: PubMed
    Score: 0.058
  19. A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America. Ocul Surf. 2022 07; 25:40-48.
    View in: PubMed
    Score: 0.049
  20. Rapamycin Eyedrops Increased CD4+Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface. Int J Mol Sci. 2020 Nov 24; 21(23).
    View in: PubMed
    Score: 0.045
  21. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000 Sep; 19(5):644-9.
    View in: PubMed
    Score: 0.044
  22. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998 Nov; 17(6):584-9.
    View in: PubMed
    Score: 0.039
  23. Advances in the diagnosis and management of keratoconjunctivitis sicca. Curr Opin Ophthalmol. 1998 Aug; 9(4):50-3.
    View in: PubMed
    Score: 0.038
  24. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis. Mol Pharm. 2016 10 03; 13(10):3468-3477.
    View in: PubMed
    Score: 0.033
  25. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014 Sep; 40(5):289-96.
    View in: PubMed
    Score: 0.029
  26. Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial. Cornea. 2013 Oct; 32(10):1297-304.
    View in: PubMed
    Score: 0.027
  27. Complications of intraocular antimicrobial agents. Int Ophthalmol Clin. 1989; 29(3):188-94.
    View in: PubMed
    Score: 0.020
  28. Endophthalmitis associated with microbial keratitis. Ophthalmology. 1996 Nov; 103(11):1864-70.
    View in: PubMed
    Score: 0.008
  29. Potential bacterial contamination in fluorescein-anesthetic solutions. Am J Ophthalmol. 1990 Aug 15; 110(2):199-202.
    View in: PubMed
    Score: 0.005
  30. Topical anesthetic abuse. Ophthalmology. 1990 Aug; 97(8):967-72.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.